Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients

This study shows the feasibility of using real-world data for the development of a population PK model. Evaluation and comparison of the model for Bayesian forecasting resulted in similar results as a model developed using rich sampling data.
Source: Journal of Pharmacokinetics and Pharmacodynamics - Category: Drugs & Pharmacology Source Type: research

Related Links:

Condition:   Acquired Hemophilia A Intervention:   Biological: TAK-672 Sponsor:   Takeda Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
NEW YORK&BRISBANE, Calif.--(BUSINESS WIRE) October 07, 2020 -- Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that the first participant has been dosed in the Phase 3 AFFINE...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
Condition:   Haemophilia A Intervention:   Drug: Turoctocog alfa pegol (N8-GP) Sponsor:   Novo Nordisk A/S Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Haemophilia A and B Intervention:   Other: NON INTERVENTIONAL Sponsor:   CHU de Reims Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Databases & Libraries | Drugs & Pharmacology | Haemophilia | Hemophilia | Study